CINECA IRIS Institutional Research Information System

BOCCADORO, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.491
EU - Europa 27.238
AS - Asia 16.619
SA - Sud America 873
AF - Africa 386
OC - Oceania 338
Continente sconosciuto - Info sul continente non disponibili 52
Totale 78.997
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.377
CN - Cina 8.829
IT - Italia 5.161
RU - Federazione Russa 3.246
DE - Germania 3.161
SE - Svezia 2.628
IE - Irlanda 2.487
SG - Singapore 2.382
FR - Francia 1.974
UA - Ucraina 1.681
JP - Giappone 1.393
FI - Finlandia 1.373
GB - Regno Unito 1.368
KR - Corea 1.344
AT - Austria 1.007
CA - Canada 819
IN - India 757
PL - Polonia 688
ES - Italia 659
VN - Vietnam 532
BR - Brasile 408
NL - Olanda 385
AU - Australia 290
HK - Hong Kong 279
TR - Turchia 272
MX - Messico 247
BE - Belgio 215
CH - Svizzera 205
GR - Grecia 203
SN - Senegal 202
DK - Danimarca 196
ID - Indonesia 196
CO - Colombia 147
PT - Portogallo 118
TW - Taiwan 117
AR - Argentina 114
IL - Israele 90
SA - Arabia Saudita 84
TH - Thailandia 74
HU - Ungheria 73
CL - Cile 71
CZ - Repubblica Ceca 64
BY - Bielorussia 63
NO - Norvegia 62
UZ - Uzbekistan 53
PE - Perù 51
MA - Marocco 50
EU - Europa 49
NZ - Nuova Zelanda 47
IR - Iran 43
RO - Romania 43
RS - Serbia 42
ZA - Sudafrica 32
EG - Egitto 30
HR - Croazia 28
PK - Pakistan 24
TN - Tunisia 23
BG - Bulgaria 22
UY - Uruguay 22
BO - Bolivia 21
EC - Ecuador 20
PH - Filippine 19
AE - Emirati Arabi Uniti 16
SI - Slovenia 16
VE - Venezuela 16
KZ - Kazakistan 14
MU - Mauritius 14
JO - Giordania 12
MK - Macedonia 12
MY - Malesia 12
BA - Bosnia-Erzegovina 11
BD - Bangladesh 10
CU - Cuba 10
KW - Kuwait 10
LT - Lituania 10
QA - Qatar 10
CR - Costa Rica 9
NG - Nigeria 9
EE - Estonia 8
LU - Lussemburgo 8
AM - Armenia 7
LK - Sri Lanka 6
PA - Panama 6
TT - Trinidad e Tobago 6
AL - Albania 5
DZ - Algeria 5
GE - Georgia 5
KE - Kenya 5
SK - Slovacchia (Repubblica Slovacca) 5
BN - Brunei Darussalam 4
GT - Guatemala 4
KY - Cayman, isole 4
MM - Myanmar 4
GF - Guiana Francese 3
IQ - Iraq 3
LB - Libano 3
NP - Nepal 3
TG - Togo 3
AD - Andorra 2
AP - ???statistics.table.value.countryCode.AP??? 2
Totale 78.952
Salva come PNG Salva come JPEG
Città #
Beijing 5.420
Chandler 3.348
Moscow 2.998
Dublin 2.451
Houston 2.264
Santa Clara 1.874
Singapore 1.826
Ashburn 1.356
Fairfield 1.342
Jacksonville 1.133
Ann Arbor 1.094
Vienna 959
Villeurbanne 944
Medford 904
Wilmington 856
Princeton 829
Nyköping 804
Torino 801
Dearborn 712
Redwood City 696
Columbus 674
Florence 674
Woodbridge 660
Seattle 577
Warsaw 563
Cambridge 498
Milan 419
San Mateo 405
Turin 366
Tokyo 347
Shanghai 340
Pisa 313
Dong Ket 310
Guangzhou 299
Fremont 284
Hangzhou 271
Toronto 268
Boardman 267
Ottawa 226
New York 225
Boston 215
Munich 214
Nanjing 199
Helsinki 194
Duncan 174
Jakarta 173
London 160
Los Angeles 155
Madrid 149
Rome 142
Norwalk 133
Brussels 128
Verona 127
Hefei 124
Bologna 120
Paris 119
Düsseldorf 113
Chicago 112
Washington 111
São Paulo 107
San Diego 104
Hong Kong 98
Chengdu 96
Falls Church 92
Zhengzhou 91
Nürnberg 82
Pune 82
Phoenix 81
Rochester 79
Barcelona 78
Istanbul 77
Wuhan 77
Changsha 75
Saint Petersburg 74
Sydney 71
Seoul 69
Hyderabad 66
Lachine 65
Amsterdam 64
Hebei 64
Frankfurt am Main 63
Philadelphia 63
Athens 62
Mumbai 62
Taipei 62
Bogotá 61
Mountain View 59
Portland 59
Central 58
Buenos Aires 57
Jinan 55
Chennai 54
Kunming 53
Indianapolis 49
Tianjin 49
Xian 48
Minneapolis 47
Shenyang 47
Nanchang 46
Padova 46
Totale 46.251
Salva come PNG Salva come JPEG
Nome #
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 3.384
Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma. 2.997
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 2.899
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 1.888
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial 1.461
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) 1.187
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma 805
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma 797
Melphalan hydrochloride for the treatment of multiple myeloma 725
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 596
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma 524
Human myeloma: kinetics of the remission phase. 513
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. 494
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors 481
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 451
Relevance of sample preparation for flow cytometry 440
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 427
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation 404
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension 397
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 392
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 336
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma 333
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. 322
Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma 319
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 310
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 306
Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease 299
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 292
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 292
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 286
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 277
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 269
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 266
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma 265
EXTRACELLULAR VESICLES AS POTENTIAL BIOMARKER FOR ACUTE GVHD 243
CLINICAL IMPACT OF IMMUNOPHENOTYPIC REMISSION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN MULTIPLE MYELOMA 239
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 238
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results 237
Determining treatment intensity in elderly patients with multiple myeloma 237
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 221
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. 221
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma 212
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 208
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib 208
FLAI induction regimen in elderly patients with acute myeloid leukemia 207
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 206
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. 205
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 205
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 205
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis 203
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 203
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 202
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 199
How is patient care for multiple myeloma advancing? 198
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 195
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 195
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 194
Ruxolitinib in steroid refractory graft-vs.-host disease: A case report 193
Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients 192
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide 190
CD38 as an immunotherapeutic target in multiple myeloma 189
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia 185
Risk of hepatitis B and efficacy of treatment with lamivudine in patients undergoing allogeneic stem cell transplant 181
Can pegylated interferon improve the outcome of polycythemia vera patients? 181
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis 181
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. 175
International staging system for multiple myeloma. 174
International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. 174
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when 174
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis 172
Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS 169
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 162
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma 162
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients 159
A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS 157
Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma 156
Anemia in the Elderly: not Always what it Seems. 155
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 155
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo) 154
Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma. 151
High CR Rate and Prolonged EFS in aaIPI 2 – 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 151
Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study 151
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 150
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial 150
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 149
Emerging drugs and combinations to treat multiple myeloma 148
null 148
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the italian bone marrow donor registry. 147
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 147
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. 146
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 145
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients 144
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS 142
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 141
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 140
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma 140
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. 137
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing 137
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 134
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts 133
Totale 37.136
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.534
article - articoli 0
book - libri 0
conference - conferenze 57.989
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 261.523
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.398 0 0 0 0 0 1.675 989 692 1.130 771 688 453
2020/20219.404 781 462 709 549 905 647 757 606 1.012 752 1.087 1.137
2021/20229.712 449 385 413 783 497 365 1.217 556 348 930 1.685 2.084
2022/202313.402 1.207 995 464 1.244 1.183 2.838 1.085 994 1.325 555 830 682
2023/20249.588 863 1.241 580 640 665 1.002 548 616 180 681 1.229 1.343
2024/202510.625 1.201 1.760 1.236 2.046 3.440 942 0 0 0 0 0 0
Totale 81.426